As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Amgen’s innovative R&D pipeline is promising, with recent approvals for IMDELLTRA™ and BLINCYTO®, and positive clinical data for TEZSPIRE® and UPLIZNA®. The pipeline features potentially ...

Amgen Inc. (NASDAQ:AMGN ... s rare disease business will continue to grow as additional indications for UPLIZNA, which treats neuromyelitis optica spectrum disorder (NMOSD), are introduced.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...